Seed, Series A
$500K – $3.0M
30+ companies
6 partners
Investment Thesis
Benelux-based healthcare investor backing biotech, medtech and digital health companies with strong science and clinical validation.
Meet the Team
Marc Lohrmann
President And General Manager
Dr. Christian Schneider
Managing Partner Vesalius Biocapital Fund 1, Fund 2 and Fund 3
Guy Geldhof
CFO Vesalius Biocapital Fund 1, Partner Fund 2 and Managing Partner Fund 3
Stéphane Verdood
Managing Partner Vesalius Biocapital Fund 1, Fund 2 and Fund 3
Dr. David Braga Malta
Venture Partner Vesalius Biocapital Fund 3
Industry Focus
Invests In
Portfolio Companies (30)
Other
Confo Therapeutics
Aphea.Bio
activaero
Developed controlled breathing technologies and inhalation devices for therapeutics.
Amakem
Developed kinase inhibitors for eye diseases using Localized Drug Action platform.
apitope
bienca
Develops enzymatic systems for food protection using bio-mimicry technology.
complix
Develops novel protein therapeutics based on proprietary Alphabody technology.
Exact Imaging
FF Pharmaceuticals
Fovea
- •Raising at Seed, Series A? You're squarely in their sweet spot.
- •Lead with your fit in Other, Healthcare, EdTech — the sectors they actively back.
- •Size your ask to their typical $500K – $3.0M check.
- •warm intro preferred
- •Address your outreach to a specific partner, such as Marc Lohrmann, President And General Manager.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if Vesalius Biocapital (Vesalius Ventures) is a match for your startup
Upload your pitch deck to see how well you match with Vesalius Biocapital (Vesalius Ventures) and 10,000+ other investors.
Is this your profile? Request a correction or removal